細胞・遺伝子治療コールドチェーンロジスティクス市場- 世界の産業規模、シェア、動向、機会、予測、2019～2029年

世界の細胞・遺伝子治療コールドチェーンロジスティクス市場は、2023年に16億8,076万米ドルと評価され、2029年のCAGRは14.11%で、予測期間中に目覚ましい成長を遂げると予測されています。

世界の細胞・遺伝子治療コールドチェーンロジスティクス市場は、主に個別化医療に対する需要の増加とバイオテクノロジーの進歩によって牽引されています。がん、遺伝性疾患、自己免疫疾患など、さまざまな疾患の治療において細胞・遺伝子治療が注目されるにつれ、効率的なコールドチェーンロジスティクスソリューションの必要性が最も高まっています。これらの治療法は、製造から患者への投与に至るサプライチェーン全体を通して、その有効性と安全性を維持するために、しばしば正確な温度制御環境を必要とします。このセグメントが進化を続ける中、コールドチェーンロジスティクスにおける革新的なアプローチは、世界中で急増する細胞・遺伝子治療の需要を満たすために極めて重要です。

主要市場の促進要因

個別化医療に対する需要の高まり

バイオテクノロジーにおける技術の進歩

規制当局の承認と商業化

医療インフラの拡大

主要市場課題

温度管理とモニタリング

サプライチェーンの複雑性と断片化

主要市場動向

コラボレーションとパートナーシップ

患者中心のアプローチ

セグメント別洞察

コンポーネント別洞察

提供サービス洞察

地域別洞察

目次

第1章 サービス概要

• 市場の定義
• 市場の範囲
  • 対象市場
  • 調査対象年
  • 主要市場セグメンテーション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 細胞・遺伝子治療コールドチェーンロジスティクスの世界市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • コンポーネント別（低温シッパー、低温保管フリーザー、超低温フリーザー、コールドチェーン管理システム、出荷・保管媒体、低温パックアウトキット、その他）
  • 提供サービス別（輸送、保管、包装）
  • 輸送形態別（航空、陸上、水上）
  • 保管温度帯別（低温、冷蔵、常温、その他）
  • エンドユーザー別（製薬バイオテクノロジー企業、学術研究機関、その他）
  • 地域別
  • 企業別（2023年）
• 市場マップ

第6章 北米の細胞・遺伝子治療コールドチェーンロジスティクス市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • コンポーネント別
  • 提供サービス別
  • 輸送手段別
  • 保持温度範囲別
  • エンドユーザー別
  • 国別
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の細胞・遺伝子治療コールドチェーンロジスティクス市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • コンポーネント別
  • 提供サービス別
  • 輸送手段別
  • 保持温度範囲別
  • エンドユーザー別
  • 国別
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋の細胞・遺伝子治療コールドチェーンロジスティクス市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • コンポーネント別
  • 提供サービス別
  • 輸送手段別
  • 保持温度範囲別
  • エンドユーザー別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の細胞・遺伝子治療コールドチェーンロジスティクス市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • コンポーネント別
  • 提供サービス別
  • 輸送手段別
  • 保持温度範囲別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの細胞・遺伝子治療コールドチェーンロジスティクス市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • コンポーネント別
  • 提供サービス別
  • 輸送手段別
  • 保持温度範囲別
  • エンドユーザー別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と新国市場開拓

• 合併買収（存在する場合）
• 製品上市（存在する場合）

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Cencora, Inc.
• United Parcel Service, Inc.
• Catalent, Inc.
• BioLife Solutions, Inc.
• Cryoport System LLC.
• Atelerix Ltd.
• Life Science Group Ltd（LSG）
• Yourway Biopharma Services Company
• Bertelsmann SE Co. KGaA
• NMDP BioTherapies

第15章 戦略的提言

第16章 戦略的提言当社について免責事項

Global Cell Gene Therapy Cold Chain Logistics Market was valued at USD 1680.76 Million in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 14.11% through 2029. Global Cell Gene Therapy ColdChain Logistics Market is primarily driven by the increasing demand for personalized medicine and advancements in biotechnology. As cell and gene therapies gain prominence in treating various diseases, including cancer, genetic disorders, and autoimmune conditions, the need for efficient cold chain logistics solutions becomes paramount. These therapies often require precise temperature-controlled environments to maintain their efficacy and safety throughout the supply chain, from manufacturing to patient administration. As the field continues to evolve, innovative approaches in cold chain logistics will be crucial to meet the escalating demand for cell and gene therapies worldwide.

Key Market Drivers

Increasing Demand for Personalized Medicine

The rising demand for personalized medicine is a significant driver of the Global Cell Gene Therapy Cold Chain Logistics Market. Cell and gene therapies are revolutionizing the treatment landscape by offering tailored solutions for various diseases, including cancer, genetic disorders, and autoimmune conditions. These therapies are designed to target specific genetic mutations or cellular abnormalities in individual patients, leading to more effective and precise treatment outcomes. As the adoption of personalized medicine continues to grow, the need for efficient cold chain logistics solutions becomes increasingly critical. Cold chain logistics ensure that these sensitive therapies are transported and stored at precise temperature-controlled environments throughout the supply chain, safeguarding their efficacy and safety. Consequently, the demand for specialized cold chain logistics services is expected to surge in tandem with the expanding market for personalized cell and gene therapies.

Technological Advancements in Biotechnology

Technological advancements in biotechnology play a pivotal role in driving the growth of the Global Cell Gene Therapy Cold Chain Logistics Market. Continuous innovations in biotechnology have led to the development of sophisticated cell and gene therapies with enhanced efficacy and safety profiles. These therapies often require specialized handling and storage conditions to maintain their potency during transportation and distribution. Cold chain logistics providers leverage advanced technologies such as temperature monitoring devices, data loggers, and real-time tracking systems to ensure the integrity of these sensitive products throughout the supply chain. Advancements in cryopreservation techniques enable the long-term storage of cellular materials at ultra-low temperatures, further expanding the scope of cold chain logistics in the cell and gene therapy sector. As biotechnology continues to evolve, cold chain logistics solutions will continue to evolve in parallel to meet the evolving demands of the market.

Regulatory Approvals and Commercialization

The attainment of regulatory approvals and commercialization milestones is driving the expansion of the Global Cell Gene Therapy Cold Chain Logistics Market. Regulatory agencies worldwide have been increasingly recognizing the therapeutic potential of cell and gene therapies, leading to accelerated approval pathways for these innovative treatments. As more therapies receive regulatory clearance for commercialization, there is a growing need for robust cold chain logistics infrastructure to support their distribution and delivery to patients. Cold chain logistics providers play a critical role in ensuring compliance with regulatory requirements related to product integrity, temperature control, and traceability throughout the supply chain. The successful commercialization of cell and gene therapies opens up new opportunities for logistics companies to collaborate with pharmaceutical manufacturers and healthcare providers, driving further market growth.

Expansion of Healthcare Infrastructure

The expansion of healthcare infrastructure, particularly in emerging economies, is fueling the demand for specialized cold chain logistics services in the Global Cell Gene Therapy Cold Chain Logistics Market. As countries invest in upgrading their healthcare systems to meet the growing needs of their populations, there is an increasing focus on improving access to advanced medical treatments, including cell and gene therapies. Cold chain logistics play a crucial role in ensuring the timely and efficient delivery of these therapies to patients, even in remote or underserved regions. The development of specialized storage and distribution facilities for cell and gene therapies within healthcare infrastructure contributes to the expansion of the cold chain logistics market. As healthcare infrastructure continues to evolve, the demand for tailored cold chain logistics solutions is expected to escalate accordingly.

Key Market Challenges

Temperature Control and Monitoring

One of the primary challenges facing the Global Cell Gene Therapy Cold Chain Logistics Market is the stringent temperature control and monitoring requirements associated with transporting and storing sensitive biological materials. Cell and gene therapies often require strict temperature ranges to maintain their efficacy and safety throughout the supply chain. However, maintaining these precise temperature conditions can be challenging, especially during long-distance transportation or when faced with unpredictable environmental conditions. Even minor deviations from the recommended temperature range can compromise the quality and integrity of the therapeutic products, rendering them ineffective or even harmful to patients. Cold chain logistics providers must deploy advanced temperature monitoring devices, data loggers, and real-time tracking systems to ensure continuous monitoring and control of temperature-sensitive shipments. Implementing contingency plans and rapid response protocols is essential to address temperature excursions and minimize the risk of product loss or damage during transit.

Supply Chain Complexity and Fragmentation

The inherent complexity and fragmentation of the supply chain pose significant challenges for the Global Cell Gene Therapy Cold Chain Logistics Market. Cell and gene therapies involve multiple stakeholders, including pharmaceutical companies, contract manufacturing organizations (CMOs), research institutions, healthcare providers, and regulatory agencies, each with distinct roles and responsibilities within the supply chain. Coordinating the activities of these diverse stakeholders and ensuring seamless integration across the supply chain is a formidable task, particularly given the specialized nature of cell and gene therapy products and the stringent logistical requirements they entail. The global nature of the cell and gene therapy market further complicates supply chain management, as shipments may traverse multiple countries and jurisdictions with varying regulatory frameworks and logistical infrastructure. Cold chain logistics providers must navigate this complexity by fostering collaboration, standardizing processes, and leveraging technology-driven solutions to enhance visibility, transparency, and traceability across the supply chain. By addressing supply chain fragmentation and improving coordination among stakeholders, cold chain logistics providers can mitigate risks and optimize the efficiency and reliability of cell and gene therapy logistics operations.

Key Market Trends

Collaborations and Partnerships

Collaborations and partnerships between pharmaceutical companies, logistics providers, and research institutions are driving innovation and market growth in the Global Cell Gene Therapy Cold Chain Logistics Market. Recognizing the complex logistical challenges associated with transporting and storing cell and gene therapies, stakeholders across the industry are increasingly joining forces to develop integrated solutions. Collaborative efforts enable the pooling of resources, expertise, and technologies to optimize cold chain logistics processes and ensure the seamless delivery of therapies to patients. Strategic partnerships facilitate knowledge sharing, risk mitigation, and capacity building within the cold chain logistics ecosystem. By fostering collaboration and innovation, these partnerships contribute to the continuous improvement of cold chain logistics infrastructure and capabilities, thereby supporting the growth of the cell and gene therapy market.

Patient-Centric Approach

The patient-centric approach adopted by healthcare providers and pharmaceutical companies is driving the demand for specialized cold chain logistics services in the Global Cell Gene Therapy Cold Chain Logistics Market. Cell and gene therapies are designed to address the specific needs of individual patients, offering personalized treatment options that are tailored to their genetic makeup and medical history. As a result, there is a growing emphasis on ensuring the timely and reliable delivery of these therapies to patients, regardless of their geographical location. Cold chain logistics providers play a crucial role in meeting this demand by offering customized solutions that prioritize patient safety, product integrity, and on-time delivery. By adopting a patient-centric approach to logistics, stakeholders in the cell and gene therapy sector can enhance patient access to life-changing treatments while maintaining the highest standards of quality and compliance.

Segmental Insights

Component Insights

Based on the Component, Cryogenic Shippers are emerging as a dominant force. Cryogenic shippers play a pivotal role in maintaining the integrity and efficacy of sensitive biological materials, such as cell and gene therapies, by providing ultra-low temperature storage conditions during transportation. These specialized containers utilize cryogenic technology to maintain temperatures as low as -196°C (-320.8°F), ensuring the preservation of cellular materials without compromising their viability or functionality. Cryogenic shippers offer several advantages that make them indispensable in the cell and gene therapy cold chain logistics ecosystem. They provide a reliable and secure means of transporting temperature-sensitive products over long distances, including international shipments. By utilizing advanced insulation materials and vacuum-sealed chambers, cryogenic shippers minimize temperature fluctuations and thermal conductivity, thereby safeguarding the integrity of the therapeutic payloads throughout the journey.

Cryogenic shippers offer flexibility and scalability to accommodate varying shipment volumes and storage requirements. Whether transporting small batches of cellular materials for clinical trials or large-scale commercial shipments, cold chain logistics providers can deploy cryogenic shippers tailored to the specific needs of their customers. Cryogenic shippers come in a range of sizes and configurations, allowing for efficient utilization of cargo space and optimization of shipping costs.

Services Offered Insights

Based on the services offered segment, transportation emerges as a dominant force due to its pivotal role in ensuring the timely and secure delivery of temperature-sensitive biologics. Transportation encompasses the movement of cellular materials, gene therapies, and related products from manufacturing facilities to distribution centers, clinical sites, and ultimately to patients. As cell and gene therapies gain prominence in the treatment landscape, the demand for specialized transportation solutions capable of maintaining precise temperature control throughout the supply chain has surged. These therapies often require ultra-low temperature storage conditions to preserve their efficacy and safety, making temperature-controlled transportation essential.

The global nature of the cell and gene therapy market adds another layer of complexity to transportation logistics. Shipments may traverse multiple countries and jurisdictions with varying infrastructure, regulatory frameworks, and logistical challenges. Therefore, cold chain logistics providers must navigate international borders, customs clearance procedures, and transportation regulations while ensuring the integrity and safety of temperature-sensitive products.

Regional Insights

The North American region, particularly the United States, stands out as the dominant region in the global cell gene therapy cold chain logistics market. Several factors contribute to North America's prominence in this sector. The United States is at the forefront of innovation and research in cell and gene therapy, with a robust ecosystem comprising leading pharmaceutical companies, biotechnology firms, academic institutions, and research organizations. The country boasts a rich pipeline of cell and gene therapy products in various stages of development and commercialization, driving the demand for specialized cold chain logistics services.

The United States has a well-established regulatory framework governed by the Food and Drug Administration (FDA), which sets stringent requirements for the transportation, storage, and handling of biologics, including cell and gene therapies. Compliance with FDA regulations is paramount for companies operating in the cell and gene therapy space, necessitating the adoption of best practices and adherence to Good Distribution Practices (GDP) to ensure product quality and patient safety.

Key Market Players

Cencora, Inc.

United Parcel Service, Inc.

Catalent, Inc.

BioLife Solutions, Inc.

Cryoport System LLC.

Atelerix Ltd.

Life Science Group Ltd (LSG)

Yourway Biopharma Services Company

Bertelsmann SE Co. KGaA

NMDP BioTherapies

Report Scope:

In this report, the Global Cell Gene Therapy Cold Chain Logistics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell Gene Therapy Cold Chain Logistics Market,By Component:

• Cryogenic Shippers
• Cryogenic Storage Freezers
• Ultra-Low Freezers
• Cold Chain Management Systems
• Shipment and Storage Medium
• Cryogenic Packout Kits
• Others

Cell Gene Therapy Cold Chain Logistics Market,By Services Offered:

• Transportation
• Storage
• Packaging

Cell Gene Therapy Cold Chain Logistics Market,By Mode of Transportation:

• Air
• Ground
• Water

Cell Gene Therapy Cold Chain Logistics Market,By Holding Temperature Range:

• Cryogenic
• Refrigerated
• Ambient
• Others

Cell Gene Therapy Cold Chain Logistics Market,By End User:

• Pharmaceutical Biotechnology Companies
• Academic Research Institutes
• Others

Cell Gene Therapy Cold Chain Logistics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell Gene Therapy Cold Chain Logistics Market.

Available Customizations:

Global Cell Gene Therapy Cold Chain Logistics market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Service Overview

• 1.1.Market Definition
• 1.2.Scope of the Market
  • 1.2.1.Markets Covered
  • 1.2.2.Years Considered for Study
  • 1.2.3.Key Market Segmentations

2.Research Methodology

• 2.1.Objective of the Study
• 2.2.Baseline Methodology
• 2.3.Key Industry Partners
• 2.4.Major Association and Secondary Sources
• 2.5.Forecasting Methodology
• 2.6.Data Triangulation Validations
• 2.7.Assumptions and Limitations

3.Executive Summary

• 3.1.Overview of the Market
• 3.2.Overview of Key Market Segmentations
• 3.3.Overview of Key Market Players
• 3.4.Overview of Key Regions/Countries
• 3.5.Overview of Market Drivers, Challenges, Trends

4.Voice of Customer

5.Global Cell Gene Therapy Cold Chain Logistics Market Outlook

• 5.1.Market Size Forecast
  • 5.1.1.By Value
• 5.2.Market Share Forecast
  • 5.2.1.By Component (Cryogenic Shippers, Cryogenic Storage Freezers, Ultra Low Freezers, Cold Chain Management Systems, Shipment and Storage Medium, Cryogenic Packout Kits, Others)
  • 5.2.2.By Services Offered (Transportation, Storage, Packaging)
  • 5.2.3.By Mode of Transportation (Air, Ground, Water)
  • 5.2.4.By Holding Temperature Range (Cryogenic, Refrigerated, Ambient, Others)
  • 5.2.5.By End User (Pharmaceutical Biotechnology Companies, Academic Research Institutes, Others)
  • 5.2.6.By Region
  • 5.2.7.By Company (2023)
• 5.3.Market Map

6.North America Cell Gene Therapy Cold Chain Logistics Market Outlook

• 6.1.Market Size Forecast
  • 6.1.1.By Value
• 6.2.Market Share Forecast
  • 6.2.1.ByComponent
  • 6.2.2.By Services Offered
  • 6.2.3.By Mode of Transportation
  • 6.2.4.By Holding Temperature Range
  • 6.2.5.By End User
  • 6.2.6.By Country
• 6.3.North America: Country Analysis
  • 6.3.1.United States Cell Gene Therapy Cold Chain Logistics Market Outlook
    • 6.3.1.1.Market Size Forecast
      • 6.3.1.1.1.By Value
    • 6.3.1.2.Market Share Forecast
      • 6.3.1.2.1.By Component
      • 6.3.1.2.2.By Services Offered
      • 6.3.1.2.3.By Mode of Transportation
      • 6.3.1.2.4.By Holding Temperature Range
      • 6.3.1.2.5.By End User
  • 6.3.2.Canada Cell Gene Therapy Cold Chain Logistics Market Outlook
    • 6.3.2.1.Market Size Forecast
      • 6.3.2.1.1.By Value
    • 6.3.2.2.Market Share Forecast
      • 6.3.2.2.1.By Component
      • 6.3.2.2.2.By Services Offered
      • 6.3.2.2.3.By Mode of Transportation
      • 6.3.2.2.4.By Holding Temperature Range
      • 6.3.2.2.5.By End User
  • 6.3.3.Mexico Cell Gene Therapy Cold Chain Logistics Market Outlook
    • 6.3.3.1.Market Size Forecast
      • 6.3.3.1.1.By Value
    • 6.3.3.2.Market Share Forecast
      • 6.3.3.2.1.By Component
      • 6.3.3.2.2.By Services Offered
      • 6.3.3.2.3.By Mode of Transportation
      • 6.3.3.2.4.By Holding Temperature Range
      • 6.3.3.2.5.By End User

7.Europe Cell Gene Therapy Cold Chain Logistics Market Outlook

• 7.1.Market Size Forecast
  • 7.1.1.By Value
• 7.2.Market Share Forecast
  • 7.2.1.By Component
  • 7.2.2.By Services Offered
  • 7.2.3.By Mode of Transportation
  • 7.2.4.By Holding Temperature Range
  • 7.2.5.By End User
  • 7.2.6.By Country
• 7.3.Europe: Country Analysis
  • 7.3.1.Germany Cell Gene Therapy Cold Chain Logistics Market Outlook
    • 7.3.1.1.Market Size Forecast
      • 7.3.1.1.1.By Value
    • 7.3.1.2.Market Share Forecast
      • 7.3.1.2.1.By Component
      • 7.3.1.2.2.By Services Offered
      • 7.3.1.2.3.By Mode of Transportation
      • 7.3.1.2.4.By Holding Temperature Range
      • 7.3.1.2.5.By End User
  • 7.3.2.United Kingdom Cell Gene Therapy Cold Chain Logistics Market Outlook
    • 7.3.2.1.Market Size Forecast
      • 7.3.2.1.1.By Value
    • 7.3.2.2.Market Share Forecast
      • 7.3.2.2.1.By Component
      • 7.3.2.2.2.By Services Offered
      • 7.3.2.2.3.By Mode of Transportation
      • 7.3.2.2.4.By Holding Temperature Range
      • 7.3.2.2.5.By End User
  • 7.3.3.Italy Cell Gene Therapy Cold Chain Logistics Market Outlook
    • 7.3.3.1.Market Size Forecast
      • 7.3.3.1.1.By Value
    • 7.3.3.2.Market Share Forecasty
      • 7.3.3.2.1.By Component
      • 7.3.3.2.2.By Services Offered
      • 7.3.3.2.3.By Mode of Transportation
      • 7.3.3.2.4.By Holding Temperature Range
      • 7.3.3.2.5.By End User
  • 7.3.4.France Cell Gene Therapy Cold Chain Logistics Market Outlook
    • 7.3.4.1.Market Size Forecast
      • 7.3.4.1.1.By Value
    • 7.3.4.2.Market Share Forecast
      • 7.3.4.2.1.By Component
      • 7.3.4.2.2.By Services Offered
      • 7.3.4.2.3.By Mode of Transportation
      • 7.3.4.2.4.By Holding Temperature Range
      • 7.3.4.2.5.By End User
  • 7.3.5.Spain Cell Gene Therapy Cold Chain Logistics Market Outlook
    • 7.3.5.1.Market Size Forecast
      • 7.3.5.1.1.By Value
    • 7.3.5.2.Market Share Forecast
      • 7.3.5.2.1.By Component
      • 7.3.5.2.2.By Services Offered
      • 7.3.5.2.3.By Mode of Transportation
      • 7.3.5.2.4.By Holding Temperature Range
      • 7.3.5.2.5.By End User

8.Asia-Pacific Cell Gene Therapy Cold Chain Logistics Market Outlook

• 8.1.Market Size Forecast
  • 8.1.1.By Value
• 8.2.Market Share Forecast
  • 8.2.1.By Component
  • 8.2.2.By Services Offered
  • 8.2.3.By Mode of Transportation
  • 8.2.4.By Holding Temperature Range
  • 8.2.5.By End User
  • 8.2.6.By Country
• 8.3.Asia-Pacific: Country Analysis
  • 8.3.1.China Cell Gene Therapy Cold Chain Logistics Market Outlook
    • 8.3.1.1.Market Size Forecast
      • 8.3.1.1.1.By Value
    • 8.3.1.2.Market Share Forecast
      • 8.3.1.2.1.By Component
      • 8.3.1.2.2.By Services Offered
      • 8.3.1.2.3.By Mode of Transportation
      • 8.3.1.2.4.By Holding Temperature Range
      • 8.3.1.2.5.By End User
  • 8.3.2.India Cell Gene Therapy Cold Chain Logistics Market Outlook
    • 8.3.2.1.Market Size Forecast
      • 8.3.2.1.1.By Value
    • 8.3.2.2.Market Share Forecast
      • 8.3.2.2.1.By Component
      • 8.3.2.2.2.By Services Offered
      • 8.3.2.2.3.By Mode of Transportation
      • 8.3.2.2.4.By Holding Temperature Range
      • 8.3.2.2.5.By End User
  • 8.3.3.Japan Cell Gene Therapy Cold Chain Logistics Market Outlook
    • 8.3.3.1.Market Size Forecast
      • 8.3.3.1.1.By Value
    • 8.3.3.2.Market Share Forecast
      • 8.3.3.2.1.By Component
      • 8.3.3.2.2.By Services Offered
      • 8.3.3.2.3.By Mode of Transportation
      • 8.3.3.2.4.By Holding Temperature Range
      • 8.3.3.2.5.By End User
  • 8.3.4.South Korea Cell Gene Therapy Cold Chain Logistics Market Outlook
    • 8.3.4.1.Market Size Forecast
      • 8.3.4.1.1.By Value
    • 8.3.4.2.Market Share Forecast
      • 8.3.4.2.1.By Component
      • 8.3.4.2.2.By Services Offered
      • 8.3.4.2.3.By Mode of Transportation
      • 8.3.4.2.4.By Holding Temperature Range
      • 8.3.4.2.5.By End User
  • 8.3.5.Australia Cell Gene Therapy Cold Chain Logistics Market Outlook
    • 8.3.5.1.Market Size Forecast
      • 8.3.5.1.1.By Value
    • 8.3.5.2.Market Share Forecast
      • 8.3.5.2.1.By Component
      • 8.3.5.2.2.By Services Offered
      • 8.3.5.2.3.By Mode of Transportation
      • 8.3.5.2.4.By Holding Temperature Range
      • 8.3.5.2.5.By End User

9.South America Cell Gene Therapy Cold Chain Logistics Market Outlook

• 9.1.Market Size Forecast
  • 9.1.1.By Value
• 9.2.Market Share Forecast
  • 9.2.1.By Component
  • 9.2.2.By Services Offered
  • 9.2.3.By Mode of Transportation
  • 9.2.4.By Holding Temperature Range
  • 9.2.5.By End User
  • 9.2.6.By Country
• 9.3.South America: Country Analysis
  • 9.3.1.Brazil Cell Gene Therapy Cold Chain Logistics Market Outlook
    • 9.3.1.1.Market Size Forecast
      • 9.3.1.1.1.By Value
    • 9.3.1.2.Market Share Forecast
      • 9.3.1.2.1.By Component
      • 9.3.1.2.2.By Services Offered
      • 9.3.1.2.3.By Mode of Transportation
      • 9.3.1.2.4.By Holding Temperature Range
      • 9.3.1.2.5.By End User
  • 9.3.2.Argentina Cell Gene Therapy Cold Chain Logistics Market Outlook
    • 9.3.2.1.Market Size Forecast
      • 9.3.2.1.1.By Value
    • 9.3.2.2.Market Share Forecast
      • 9.3.2.2.1.By Component
      • 9.3.2.2.2.By Services Offered
      • 9.3.2.2.3.By Mode of Transportation
      • 9.3.2.2.4.By Holding Temperature Range
      • 9.3.2.2.5.By End User
  • 9.3.3.Colombia Cell Gene Therapy Cold Chain Logistics Market Outlook
    • 9.3.3.1.Market Size Forecast
      • 9.3.3.1.1.By Value
    • 9.3.3.2.Market Share Forecast
      • 9.3.3.2.1.By Component
      • 9.3.3.2.2.By Services Offered
      • 9.3.3.2.3.By Mode of Transportation
      • 9.3.3.2.4.By Holding Temperature Range
      • 9.3.3.2.5.By End User

10.Middle East and Africa Cell Gene Therapy Cold Chain Logistics Market Outlook

• 10.1.Market Size Forecast
  • 10.1.1.By Value
• 10.2.Market Share Forecast
  • 10.2.1.By Component
  • 10.2.2.By Services Offered
  • 10.2.3.By Mode of Transportation
  • 10.2.4.By Holding Temperature Range
  • 10.2.5.By End User
  • 10.2.6.By Country
• 10.3.MEA: Country Analysis
  • 10.3.1.South Africa Cell Gene Therapy Cold Chain Logistics Market Outlook
    • 10.3.1.1.Market Size Forecast
      • 10.3.1.1.1.By Value
    • 10.3.1.2.Market Share Forecast
      • 10.3.1.2.1.By Component
      • 10.3.1.2.2.By Services Offered
      • 10.3.1.2.3.By Mode of Transportation
      • 10.3.1.2.4.By Holding Temperature Range
      • 10.3.1.2.5.By End User
  • 10.3.2.Saudi Arabia Cell Gene Therapy Cold Chain Logistics Market Outlook
    • 10.3.2.1.Market Size Forecast
      • 10.3.2.1.1.By Value
    • 10.3.2.2.Market Share Forecast
      • 10.3.2.2.1.By Component
      • 10.3.2.2.2.By Services Offered
      • 10.3.2.2.3.By Mode of Transportation
      • 10.3.2.2.4.By Holding Temperature Range
      • 10.3.2.2.5.By End User
  • 10.3.3.UAE Cell Gene Therapy Cold Chain Logistics Market Outlook
    • 10.3.3.1.Market Size Forecast
      • 10.3.3.1.1.By Value
    • 10.3.3.2.Market Share Forecast
      • 10.3.3.2.1.By Component
      • 10.3.3.2.2.By Services Offered
      • 10.3.3.2.3.By Mode of Transportation
      • 10.3.3.2.4.By Holding Temperature Range
      • 10.3.3.2.5.By End User

11.Market Dynamics

• 11.1.Drivers
• 11.2.Challenges

12.Market Trends Developments

• 12.1.Merger Acquisition (If Any)
• 12.2.Product Launches (If Any)
• 12.3.Recent Developments

13.Porter's Five Forces Analysis

• 13.1.Competition in the Industry
• 13.2.Potential of New Entrants
• 13.3.Power of Suppliers
• 13.4.Power of Customers
• 13.5.Threat of Substitute Products

14.Competitive Landscape

• 14.1.Cencora, Inc.
  • 14.1.1.Business Overview
  • 14.1.2.Company Snapshot
  • 14.1.3.Products Services
  • 14.1.4.Financials (As Reported)
  • 14.1.5.Recent Developments
  • 14.1.6.Key Personnel Details
  • 14.1.7.SWOT Analysis
• 14.2.United Parcel Service, Inc.
• 14.3.Catalent, Inc.
• 14.4.BioLife Solutions, Inc.
• 14.5.Cryoport System LLC.
• 14.6.Atelerix Ltd.
• 14.7.Life Science Group Ltd (LSG)
• 14.8.Yourway Biopharma Services Company
• 14.9.Bertelsmann SE Co. KGaA
• 14.10.NMDP BioTherapies

15.Strategic Recommendations

16.About Us Disclaimer